Tuesday, November 10, 2015
- 9:00AM-11:00AM
-
Abstract Number: 2220
Appropriate Investigations and Costs in Rheumatology: Residents’ Attitudes and Knowledge
Education Poster II- 9:00AM-11:00AM
-
Abstract Number: 2849
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy- 9:00AM-11:00AM
-
Abstract Number: 2888
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy- 9:00AM-11:00AM
-
Abstract Number: 2889
Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Improvements in Nail and Scalp Psoriasis and Psoriasis Area and Severity Index in Patients with Moderate to Severe Plaque Psoriasis
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy- 9:00AM-11:00AM
-
Abstract Number: 2385
Arthritis Management in Primary Care and Adherence to National Guidelines – a Swedish Survey Based on the Canadian Physiotherapists Arthritis Care Questionnaire
Orthopedics, Low Back Pain and Rehabilitation Poster (ARHP): Rehabilitation Sciences- 9:00AM-11:00AM
-
Abstract Number: 2661
Assessing Information Needs for Chronic Disease Management in Rheumatoid Arthritis
Rheumatoid Arthritis - Clinical Aspects Poster Session III- 9:00AM-11:00AM
-
Abstract Number: 2412
Assessment and Comparison of Responsiveness of Four Patient Reported Outcome Measures to Assess Physical Function in Patients with Knee Osteoarthritis: WOMAC-PF Subscale Responds Best
Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research- 9:00AM-11:00AM
-
Abstract Number: 2891
Assessment of Disability Levels in a Cohort of 1,489 Patients with Active Psoriatic Arthritis, and the Effect of Apremilast Treatment: Pooled Data from Three Phase III, Randomized, Controlled Trials
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy- 9:00AM-11:00AM
-
Abstract Number: 12L
Assessment of Immunogenicity of Live Zoster Vaccination (Zostavax®) in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo
ACR Late-breaking Abstract Poster Presentations- 9:00AM-11:00AM
-
Abstract Number: 2990
Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III- 9:00AM-11:00AM
-
Abstract Number: 2980
Assessment of Sublingual Frenulum Perfusion in Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III- 9:00AM-11:00AM
-
Abstract Number: 2751
Assessment of the Effect of CYP3A Inhibition, CYP Induction, OATP1B Inhibition and Administration of High-Fat Meal on the Pharmacokinetics of the Potent and Selective JAK1 Inhibitor ABT-494
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III- 9:00AM-11:00AM
-
Abstract Number: 2196
Association Between Antiphospholipid Antibodies and All-Cause Mortality Among End Stage Renal Disease Patients with and without SLE
Antiphospholipid Syndrome: Clinical- 9:00AM-11:00AM
-
Abstract Number: 2684
Association Between Anxiety and Depression and Rheumatoid Arthritis Outcome: Results from an Inception Early Rheumatoid Arthritis Cohort